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Background. Progressive multifocal leukoencephalopathy (PML) in natalizumab-treated MS patients is linked to
JC virus (JCV) infection. JCV sequence variation and rearrangements inﬂuence viral pathogenicity and tropism. To
better understand PML development, we analyzed viral DNA sequences in blood, CSF and/or urine of natalizumab-
treated PML patients.
Methods. Using bioﬂuid samples from 17 natalizumab-treated PML patients, we sequenced multiple isolates of
the JCV noncoding control region (NCCR), VP1 capsid coding region, and the entire 5 kb viral genome.
Results. Analysis of JCV from multiple bioﬂuids revealed that individuals were infected with a single genotype.
Across our patient cohort, multiple PML-associated NCCR rearrangements and VP1 mutations were present in CSF
and blood, but absent from urine-derived virus. NCCR rearrangements occurred in CSF of 100% of our cohort. VP1
mutations were observed in blood or CSF in 81% of patients. Sequencing of complete JCV genomes demonstrated
that NCCR rearrangements could occur without VP1 mutations, but VP1 mutations were not observed without
NCCR rearrangement.
Conclusions. These data conﬁrm that JCV in natalizumab-PML patients is similar to that observed in other PML
patient groups, multiple genotypes are associated with PML, individual patients appear to be infected with a single
genotype, and PML-associated mutations arise in patients during PML development.
The emergence of progressive multifocal leukoence-
phalopathy (PML) in multiple sclerosis (MS) patients
treated with natalizumab has motivated a search for
biological factors contributing to the risk of this serious
brain infection. PML is caused by the JC virus (JCV),
which is estimated to be present in 50%–60% of the
world’s adult population [1–3]. In infected individuals,
JCV can persist and replicate asymptomatically in the
urinary tract and possibly other organs [4]. In immu-
nocompetent individuals, the virus is rarely found
outside of the urinary tract [5]. However, under
conditions of severe immunosuppression or treatment
with speciﬁc immunomodulating drugs, the virus may
establish a lytic infection in oligodendrocytes, leading to
PML [6, 7].
Although the percentage of people infected with JCV
is high, PML is a rare disease. It is most widely seen in
HIV/AIDS patients in whom the lifetime incidence
ranges from 3% to 5% [8, 9], although these numbers
have begun to decline with the use of combined anti-
retroviral therapy [10]. In the past decade, however, an
increasing number of non–HIV/AIDS–related cases of
PML have been reported. Many of these newcases occur
in individuals on new and emerging immunomodulat-
ing therapies [11]. In 2005, 3 cases of PML were re-
ported in patients undergoing natalizumab therapy for
MS or Crohn’s disease [12–14]. PML has also been
linkedto other immunomodulatingtherapies, including
efalizumab, mycophenolate mofetil, and rituximab [15].
Since 2005, 108 additional cases of PML associated with
natalizumab therapyhavebeenreported.Natalizumabis
a humanized monoclonal antibody that limits the entry
of immune cells to the central nervous system (CNS) by
binding to the alpha-4 chain of integrin molecules and
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endothelial cells of the blood-brain barrier [16]. Initially,
natalizumab-associated PML was reported in patients on com-
bination therapy, but all subsequent cases have occurred in
patients on monotherapy [17]. While the presence of JCV has
beenestablishedin allconﬁrmedcasesofnatalizumab-associated
PML, the DNA sequences of the viruses have not been reported.
JC virus is a member of the genus Polyomavirus, which
includes JCV, BK virus, WU virus, KI virus, Merkel cell poly-
omavirus, Simian Virus 40, and mouse polyomavirus [18]. The
genome is a double-stranded, circular DNA molecule of roughly
5100 bases. The genome encodes 6 proteins and can be divided
into 3 segments: early genes, late genes, and a noncoding control
region (NCCR; also known as the transcription control region,
or TCR) [19]. The proteins encoded by the early region genes
(small t-antigen and large T-antigen) are involved in viral rep-
lication and transcription of the late region genes. The late genes
encode the capsid proteins VP1, VP2, and VP3, as well as the
regulatory protein agnoprotein. The NCCR includes the origin
of replication, as well as sequences that control transcription of
both early and late genes. Within individual hosts, JCV persists
in at least 2 forms: a latent, nonpathogenic form and a virulent
neurotropic form. The neurotropic form contains a rearranged
NCCR and is typically found in the cerebrospinal ﬂuid (CSF),
brain, or blood of PML patients. The nonpathogenic form is
most frequently detected in urine, and its NCCR is not
rearranged [20]. NCCR rearrangements involve deletions and
duplications of speciﬁc sequence elements (reviewed by Yogo
and colleagues [21]) and are thought to play a role in the
pathogenesis of the virus by altering its cellular tropism. More
recently, observations of point mutations in the VP1 capsid
protein have also been shown to be associated with PML
[22–25]. Currently there is no consensus on whether speciﬁc
JCV genotypes are preferentially associated with PML [26–32],
and existing literature does not address the question of whether
the pathogenic form is acquired as a new infection or if it arises
from alterations of latent virus.
To better understand the emergence of the pathogenic form
of JCV in natalizumab-treated patients, we conducted a cross-
sectional study, incorporating samples obtained at or near the
time of PML diagnosis. We isolated and sequenced JCV from
available plasma, urine, and CSF samples of 17 PML patients.
Using a combination of locus-speciﬁc and whole viral genome
analysis, we obtained data on JCV genotype, NCCR rearrange-
ment,andVP1capsidproteinsequencevariation.Toanalyzethe
JC virus associated with natalizumab-treated PML patients, we
sequencedviralisolatesfromurine,blood,andCSFofindividual
patients wherever all 3 were available. Our analysis of multiple
sequences, often from more than 1 anatomical location in
individual patients, provides new insights into JCV sequence
diversity, features of NCCR rearrangements, and the relation-
ship between NCCR rearrangement and VP1 point mutations.
METHODS
Samples
CSF, plasma, serum, and urine samples were obtained from
natalizumab-treated MS patients suspected of having or con-
ﬁrmed to have PML. All samples were kept frozen and thawed
on ice prior to use for extraction of viral DNA.
Viral DNA Extraction
JCV DNA was extracted from bioﬂuids using commercial kits
according to the manufacturers published protocols. For
extraction of viral DNA from urine (3.5 mL) samples, the
QIAamp Viral RNA Mini Kit was used (Cat 52904; Qiagen,
Inc.). For all other samples (CSF, plasma) we used the QIAamp
MinElute Virus Spin Kit (Cat 57704; Qiagen, Inc.).
Polymerase Chain Reaction (PCR) Amplification
For ampliﬁcation of the NCCR and VP1 coding sequences from
the viral DNA, we used the Herculase II Fusion Enzyme system
(Cat 600677; Agilent Technologies, Inc.). For NCCR ampliﬁca-
tion we used the following primers: 5# GATTCCTCCCTATT-
CAGCACTTTG 3#and 5# TCCACTCCAGGTTTTACTAA 3#.
The entire VP1 coding region was ampliﬁed with the following
primers: 5# CCTCAATGGATGTTGCCTTT 3# and 5# AAAAC-
CAAAGACCCCTC 3#.
Cloning and Sequencing
PCR ampliﬁcation products were cloned using the TOPO TA
Cloning Kit for sequencing (Cat 45-0030; Qiagen, Inc.). Prior to
ligation of the PCR products into the TOPO vector, 3# terminal
adenines were added to the insert by incubation with Taq
polymerase and additional deoxyribonucleotide triphosphates
(dNTPs) for 15 minutes at 72C. Ligation products were
transformed and plated according to manufacturer’s speciﬁca-
tions. When possible, up to 48 individual colonies for each
cloned product were screened and sequenced by Applied Bio-
systems 3730XL DNA Analyzer with BigDye Terminator version
3.1 chemistry.
Viral Sequence Accession Numbers
All viral sequences have been deposited into GenBank and as-
signed the following accession numbers: JF424834 – JF426135.
JCV Whole Genome Amplification
Whole genome ampliﬁcation of JCV was accomplished in
3 steps using a modiﬁcation of the protocol from Agostini HT,
Stoner, GL [33]. In the ﬁrst step, template DNA was ampliﬁed
by multiple displacement ampliﬁcation (MDA) using the RE-
PLI-g kit (Cat 150043; Qiagen, Inc.). In the second step, the
MDA product was linearized by digestion with a single cutting
enzyme, EcoR1, which resulted in fragments of whole genome
length. In the ﬁnal step, the fragments were used as a template
for full-length genome ampliﬁcation using Phusion Hot Start
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We used the following primers (the EcoR1 sites are in bold):5#
GTTTCTTAGAATTCCACTACCCAATCTAAATGAGGAT 3#
and 5# GTTTCTTTGGAATTCTGGCCACACTGTAACAAG 3#.
PCR products of appropriate length were conﬁrmed by gel
electrophoresis, cloned, and sequenced.
Data Analysis
The determination of JCV genotype was based on known
polymorphisms in the VP1 capsid coding sequence [34]. Gen-
otypes were deﬁned by alignment and degree of identity to re-
ported genotypes at 12 amino acid positions. When the VP1
sequences were not perfectly matched to any of the genotypes,
we mapped them to the nearest genotype and appended a ‘‘v’’ to
indicate they were variants of a standard JCV genotype. To
conﬁrm strain designations we performed phylogenetic analysis
on our VP1 sequences and found that all isolates from the same
genotype clustered together (data not shown). Outside of the
genotype deﬁning sites, any variations in VP1 were compared
with a VP1 variability table [23], which identiﬁed amino acid
positions that were hypervariable in virus derived from PML
patients compared with non-PML patients.
For analysis of the NCCR, the sequences were aligned and
mapped to the archetype JCV NCCR [35]. The 267 bases of the
archetype are commonly divided into segments to describe
recurrent patterns of deletion and duplication [27, 32, 36]. The
7regions areORI,A,B,C,D,E,andFsequentiallyfrom5#to3#.
We used the combinations of letters to describe different NCCR
patterns. In our notation, a capital letter in the NCCR pattern
represents a perfect match to the corresponding region of the
archetype sequence, while a lowercase letter indicates a region
with deletion, and an asterisk denotes a point mutation.
For whole genome analysis, we used the MargFreq (software)
Program to score and annotate amino acid positions that varied
across the groups of genomic sequences. In total, 396 individual
JCV whole genome sequences were retrieved from Genbank
(25 from brain, 371 from urine), translated into individual viral
protein sequences, and compared with 152 individual viral
genome sequences from Tysabri PML patients.
RESULTS
Comparative analysis of JCV within and among natalizumab-
treated PML patients showed that patterns of DNA sequence
variation are similar to what has been observed in AIDS and
other PML patients. CSF, blood, and urine samples from
natalizumab-treated PML patients were collected at or near the
time of diagnosis. To maximize the use of samples, we
performed 3 independent ampliﬁcations on each viral DNA
sample: NCCR, VP1, and whole genome. At least 1 of these
reactions succeeded for samples from 17 natalizumab-treated
PML patients. Whole JCV genomes were successfully ampliﬁed
from 6 PML patients. Independent ampliﬁcations of the VP1
region (without whole genome ampliﬁcation) were completed
for 16 patients, and for 13 patients we obtained both VP1 and
NCCR sequence data (Table 1). The 6 patients from which the
JCV whole genome was sequenced also have independently
derived VP1 and NCCR sequences that matched the sequences
found on the whole genomes. All sequence data were obtained
from an average of 16 isolates of cloned PCR products.
We controlled for cross-contamination by including a ‘‘buffer-
alone’’ sample each time we performed the viral DNA extraction
and PCR ampliﬁcation protocols. Analysis of the NCCR
sequence data revealed that every viral DNA sample that was
rearranged had a unique NCCR sequence. This served as an
internal control for our NCCR ampliﬁcation reactions and
conﬁrmed that none of our NCCR sequences matched the
Mad-1 laboratory strain. While the most frequently observed
genotype was type 1B, found in 7 patients, we did not observe
a relationship between JCV genotype and PML development
(Table 1).
NCCR Sequences
As shown in Table 1, we obtained NCCR sequences from
25 PML samples (14 patients). Five samples were from urine, 11
from CSF, and 9 from blood. For most samples, the PCR
products were cloned and as many as 47 isolates sequenced. We
sequencedatotalof579NCCRsequences. Consistentwithother
studies [20, 22], we found that all NCCR sequences from urine
samples matched the archetype sequence. In contrast, all
sequences from PML-associated CSF or blood were rearranged,
containing deletions, tandem repeats, or both relative to the
archetype reference sequence. In certain patients, we observed
multiple patterns of NCCR rearrangement in a given compart-
ment(ie,CSForblood)(Table1;Figure1A–C).Insomeofthese
patients, the more common variant in each body compartment
was identical. Analysis of how these rearrangements impacted
transcription factor binding sites within the JCV NCCR revealed
that the NF-1 binding site was the most frequently duplicated,
with other sites such as AP-1 and SP-1 being less affected (see
Supplemental Material). While the NCCR rearrangements
were distinct from one patient to another, the most frequent
events involved deletions of all or part of segment D. Deletion
of all or part of segment D occurred in all but 1 rearranged
virus from the CSFor blood of all the PML patients we studied
(Figure 2).
VP1 Sequences
We and others have shown that mutations near the sialic acid
binding pocketoftheviralVP1 capsidprotein may beassociated
with PML development [22, 23]. We sequenced the entire VP1
coding region of JCV DNA isolated from blood, CSF, and/or
urine of 16 patients. Our ﬁndings are summarized in Table 1.
Eighty-one percent of patients (13/16) had VP1 point muta-
tions. For patients with urine, as well as blood or CSF sequences,
the mutationswerenotdetectedinvirusfromurine.Nearly50%
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residues known to be important for sialic acid binding by JCV
[22, 23, 38–41]. The other VP1 mutations observed, though less
frequent, were in positions where mutations associated with
PML have been reported elsewhere [22].
JCV Whole Genome Analysis
Eight samples from 6 patients were suitable for whole genome
ampliﬁcation and sequencing (Table 2). For each sample we
ampliﬁed and cloned the genome, followed by sequencing be-
tween 2 and 45 individual isolates. We looked for evidence of
Table 1. Patient Samples, Strain Type, and Mutational Status of JC Viruses From 17 Natalizumab-Treated PML Subjects
VP1 NCCR
ID Matrix Genotype Mutation No. of Clones TCR Pattern No. of Clones
PML-001 CSF 2B WT 48 R ORI_A_b_c_c_e_f 44
PML-002 CSF 1B D66H 41 – – –
PML-004 PLASMA 1BV WT 26 – – –
URINE 1BV WT 50 A ORI_A_B_C_D_E_F 39
PML-005 CSF 1B D66G 48 – – –
PML-006 CSF
a 1AV WT 3 R ORI_A_B_c_d_e_b_c_d_E_f 32
L55F 25 ORI_A_B_c_d_E_f 1
N265S 7
L55F, N265S 4
SERUM 1AV S267F 24 R ORI_A_B_c_d_e_b_c_d_E_f 38
ORI_A_B_c_d_E_f 1
PML-007 CSF
a 1B S269F 6 R ORI_A_B_c_c_E_F 20
PML-009 CSF
a 1A S267L 5 R ORI_A_B_C_d_E_f_c_d_E_f 18
ORI_A_B_C_d_e_c_d_e_f 3
ORI_A_B_C_d_E_f_c_d_E_f_c_d_E_f_c_d_E_f 1
PLASMA 1A S267L 23 R ORI_a_b_c_c_F 23
URINE
a 1A WT 2 A ORI_A_B_C_D_E_F 22
PML-012 CSF 1B L55F 17 R ORI_A_C*_E_a_C*_E_f 21
PLASMA – – – R ORI_A_C*_E_a_C*_E_f 20
URINE
a 1B WT 22 A ORI_A_B_C_D_E_f 13
PML-013 PLASMA
a 1AV L55F 21 R ORI_A_B_c_f_c_E_f 30
URINE
a 1AV WT 23 A ORI_A_B_C*_D_E_f 17
PML-019 CSF
a 2B S61P 46 R ORI_A_B_c_d_e_f_b_c_d_e_F 23
SERUM 2B S61P, S61T 19 R ORI_A_B_c_d_e_f_c_d_e_f 9
ORI_A_B_c_d_e_f 1
URINE 2B WT 1 – – –
PML-021 CSF
b 1A S269F 1 R ORI_A_B_c_d_E_F 21
PLASMA
b 1A S269F 1 – – –
PML-022 CSF 1A WT 46 R ORI_A_B_C_E_C_E_f 21
PML-025 CSF
b 2AV S269F 1 R ORI_A_B*_C_D_E_f_f 22
SERUM 2AV S269F 1 R ORI_A_B*_C_D_E_f_f 24
PLASMA 2AV S269F 1 R ORI_A_B*_C_D_E_f_f 24
URINE 2AV WT 1 A ORI_A_B_C*_D_E_F 1
PML-030 CSF
b 1B S267F, Q271H 1 R ORI_A_B_c_E_f_b_c_E_F 25
PML-032 CSF – – – R ORI_A_B_c_b_c_E_F 23
PLASMA – – – R ORI_A_B_c_b_c_E_c_E_f 22
ORI_A_B_c_b_c_E_f 1
PML-033 SERUM 1BV L55F, Q271K 23 R ORI_A_B_c_e_b_c_E_F 7
ORI_A_B_c_e_c_E_F 6
ORI_A_B*_C_e_c_E_F 5
ORI_A_B_c_e 1
142–101 PLASMA 2B L55F 5 – – –
Total 542 579
NOTE. Summary of viral sequence data. VP1 coding region and transcriptional control regions were PCR ampliﬁed, cloned, and sequenced. The number of clones
sequenced for each ampliﬁcation is indicated. All sequences were compared with reference genotype NC_001699 (Genbank). Wild-type (WT), rearranged( R ) ,
archetype (A), no data (-). The NCCR patterns are described using letters to designate NCCR segments (Frisque and Yogo), and are described further in the Methods
section. Capital letters indicate that a segment is identical to the reference archetype. Lowercase letters indicate that a segment has an insertion or deletion.
Asterisks (*) indicate a point mutation or single nucleotide polymorphism relative to the reference archetype.
a Sequenced JCV whole genome from this sample.
b Sample not cloned (sequenced bulk PCR product). CSF, cerebrospinal ﬂuid; NCCR, noncoding control region; PCR, polymerase chain reaction; PML,
progressive multifocal leukoencephalopathy; TCR, transcription control region.
240 d JID 2011:204 (15 July) d Reid et alcomutations between the NCCR and VP1 coding regions and
for mutations in the 5 other protein coding genes (agnoprotein,
VP2, VP3, large T- and small t-antigens) that might suggest the
involvement of these viral proteins in the development of PML.
We compared the JCV genomic sequences of natalizumab-
treated PML patients to publicly available JCV genomes. JCV
genomes derived from CSF samples were the most heteroge-
neous, while urine-derived genomic sequences were relatively
homogeneous. In every case, the VP1 and NCCR sequences
from whole genomes matched their counterparts from the tar-
geted sequencing (Tables 1 and 2). We found 2 novel variants
(T125A, C560S) in the large T coding region among the ge-
nomes we sequenced (Table 3; online only). All other coding
variants observed in the natalizumab-treated PML patient ge-
nomes were at sites of known genotype-speciﬁc heterogeneity.
DISCUSSION
This is the ﬁrst detailed study of JCV sequence variation in nata-
lizumab-associated PML. In 17 natalizumab patients from the
United States and Europe, we observed 6 different JCV genotypes
or genotype variants. The most frequently observed genotype was
Figure 1. Example of NCCRs from different biofluids of 3 natalizumab-
treated PML patients. A, Archetype and Mad-1 NCCRs (shown for
comparison); B, PML-012; C, PML-006; and D, PML-032. Urine-derived
sequences always matched archetype, while sequences from CSF and
blood were often identical to each other or contained related pat-
terns of rearrangement. Letter designations and numbering for NCCR
segments are described in Table 1 and in Methods section. CSF,
cerebrospinal fluid; NCCR, noncoding control region; PML, progressive
multifocal leukoencephalopathy.
Figure 2. TheNCCRfromCSForbloodofPMLpatientsfrequentlycontained
deletionofallorpartofregionD.A, Schematic of region D from CSF samples.
B, schematic of region D from blood samples. Numbering according to Yogo
and colleagues and Frisque and colleagues [20, 37]. CSF, cerebrospinal fluid;
NCCR, noncoding control region; PML, progressive multifocal leukoencephal-
opathy.
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notypeintheUnitedStatesandEurope[28, 42]. We also observed
g e n o t y p e s1 A ,1 A V ,1 B V ,2 A V ,a n d2 B .A l t h o u g ht h i si sal i m i t e d
sample set, it does not appear that particular geographic geno-
types are associated with PML in our patient cohort.
JCV in natalizumab-treated PML patients appears to be
similar to that in AIDS and other PML patients, with the most
variable regions of the viral genome being the NCCR and VP1
coding sequences. Rearrangements of the NCCR were observed
in 100% of the virus isolated from CSF or blood (Table 1).
Mutations in the VP1 capsid protein were found in virus iso-
lated from the CSF or blood of 13 (81%) of 16 patients analyzed
and were not found in urine. In5 patientswe had matchedurine
andnonurine samplesinwhichtheVP1mutationwaspresentin
the blood and/or CSF but not present in the urine. Each of these
patients hadasingle genotype ofvirus,suggestingwithin-patient
changes in this gene.
While both NCCR rearrangements and VP1 point mutations
were prevalent in JCV from the CSF and/or blood of natalizu-
mab-treated PML patients, the NCCR changes were more
common and appeared to precede VP1 mutations. This was
suggested by whole genome data that showed a variety of VP1
mutations in the background of a constant NCCR pattern
(Table 2, Figure 3). Also, 2 of the 3 PML patients without VP1
mutations had NCCR rearrangements (the other subject’s
NCCR failed to amplify).
The NCCR sits between the viral early gene large T and the
late gene agnoprotein and is 267 base pairs in the archetype JCV
sequence. The 267 bases are commonly divided up into
6 unequal fragments, A–F, facilitating the description of re-
current patterns of deletion and duplication [27, 32, 36].
Analysis of the NCCR regions of our PML cohort revealed
a variety of rearranged patterns, with each patient having
a unique pattern of deletions and duplications (Table 1). Seg-
ment D was the most commonly affected segment, being par-
tially or completely deleted in CSF or blood of 12 (92%) of 13
patients(Figure2). SegmentB wasalsofrequentlydeleted. These
observations are consistent with NCCR rearrangements seen in
AIDS patients with PML [43].
In cases where more than 1 rearranged NCCR pattern was
present in a sample, we often observed a short form of the
NCCR, with deletion but no duplication, and a long form with
both deletion and duplication (Figure 1C,1 D). This observation
suggests that deletions may occur prior to duplication in the
process of NCCR rearrangement. In patients from whom we
obtained NCCR sequences from both CSF and blood, most
contained similar or identical NCCR rearrangement patterns
across those bioﬂuids within the individual patients. While this
suggeststhatthe rearrangedvirusspreadfromonecompartment
to the other, our data do not reveal exactly where in the host
NCCR rearrangements occur. They may occur outside of the
CNS and travel through the blood, or they may occur ﬁrst in the
CNS with subsequent release into the blood. Indeed, it also
remains possible that viral mutations may occur transiently in
the urinary tract (or bone marrow) [15] prior to release to other
organ systems. Longitudinal studies combined with deep
sequencing of viral populations may help reveal the sequence of
mutational events leading to changes in tissue tropism and
behavior of JCV.
Our analysis of complete JCV genomic sequences from 6
natalizumab-treated patients revealed several important features
Table 2. NCCR and VP1 Mutation Patterns Observed in Full-
Length JC Virus Sequences From 6 Natalizumab-Treated PML
Patients
ID Matrix Genotype NCCR VP1
No. of
Clones
PML-006 CSF 1AV R L55F 18
N265S 9
S269Y 1
WT 10
PML-007 CSF 1B R S269F 7
PML-009 CSF 1A R S267L 20
Urine 1A A WT 17
PML-012 Urine 1B A WT 2
PML-013 Plasma 1AV R L55F 45
Urine 1AV A WT 6
PML-019 CSF 2B R P51S 8
S61P 9
Total 152
NOTE. Summary of JCV whole genome sequence data. Wild-type (WT),
rearranged (R), archetype (A). For each of these samples, we also obtained
results from PCR and cloning of NCCR and VP1 independently, and those data
are represented in Table 1. For all genomic clones a single species of TCR was
seen in each sample matching the pattern described in Table 1. CSF,
cerebrospinal ﬂuid; NCCR, noncoding control region; PCR, polymerase chain
reaction; PML, progressive multifocal leukoencephalopathy.
Figure 3. PML-associated mutations develop within individual hosts.
Comparison of VP1 and NCCR sequences from whole genomes of
a natalizumab-treated PML patient (PML-006). Analysis of virus from
different biofluids showed that this patient was infected with a single
viral genotype and that PML-associated mutations were present in virus
found outside of the urine. While multiple VP1 capsid mutations were
observed, all mutated viral species contained identical NCCR rearrange-
ments. NCCR, noncoding control region; PML, progressive multifocal
leukoencephalopathy; WT, wild type.
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NCCR rearrangement without VP1 mutation, but never the
opposite. Additionally, we did not observe any pattern of NCCR
rearrangement associated with speciﬁc VP1 capsid mutations or
JCV genotypes. This suggests that NCCR rearrangement and
VP1 mutation may be independent events that impact distinct
elementsofJCV cellulartropism.However,sinceVP1mutations
have not been observed in JCV with archetype NCCR, VP1
mutations may only arise in JCV with the pathogenic forms of
NCCR. With 2 exceptions the sequence variations observed in
protein-coding genes other than VP1 were previously described
genotype-associated polymorphisms. In 1 patient (PML-013),
the virus contained a novel T125A mutation in the gene en-
coding the large T-antigen protein. In a second patient (PML-
019), we observed a C560S mutation, also in large T-antigen
(Table3;onlineonly).Bothofthesemutationsoccurredinmore
than 1 clonal isolate, and neither was found in a search of
published JCV T-antigen sequences (Genbank). The importance
of these sequence variants is unknown at this time.
PML-associated mutations were notably absent from virus in
the urine of natalizumab-treated PML patients. The pattern
observed for PML patients is essentially the same as that ob-
served for AIDS and other PML patients: Only archetype virus
is detected in urine, and, post-PML diagnosis, rearranged or
mutated virus is observed in the bloodstream and CSF, but not
in urine. This observation suggests that if NCCR rearrangement
ever occurs in the urinary tract, it is rare and is not subject to
preferential selection over archetypal virus replication. This is in
sharp contrast to a recent description of virus with rearranged
NCCR in the urine of a non-PML MS patient treated with nata-
lizumab [44]; the reasons for this discrepancy are not understood at
the moment. However, in the unusual case where rearranged virus
was reported in urine, it was not associated with PML.
While the immunological perturbations leading to PML in
natalizumab-treated MS patients and in AIDSpatients appear to
be different, the patterns of DNA sequence variation that we
observed are strikingly similar. We have shown that in
natalizumab-treated PML patients, VP1 mutations and the
previously reported NCCR rearrangements are the most com-
mon viral alterations associated with PML. Our data are con-
sistent with the model of a common asymptomatic infection
with archetype JC virus, frequently found in urine, combined
with a rare occurrence of changes in the viral genome that can
alter cellular tropism and potentially lead to CNS infection and
PML. Since our data are derived from samples that were col-
lected at or near the time of PML diagnosis, it remains to be
determined if any of the mutations we observe appear prior to
the clinical manifestations of PML. Our ﬁndings broaden the
information available on JCvirus and PML and may be usefulin
the contextof earlier diagnosis of PML or in predicting who is at
greater risk for developing PML. Additional research into tissue
distribution of JCV in healthy patients, and patients with
immune diseases such as HIV or MS, as well as longitudinal
studies of patients on therapies associated with PML, will un-
doubtedly reveal even more about JCV and PML. Combined
with these translational approaches, improved methods for the
detection of low levels of viral DNA may help stratify PML risk
and guide therapeutic strategies.
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